MAVENCLAD® (Cladribine Tablets) Approved As The First Short-Course Oral Treatment for Relapsing Remitting Multiple Sclerosis in Switzerland

Darmstadt, Germany (ots/PRNewswire) – MAVENCLAD® is now approved in 52 countries worldwide Approval brings forward new treatment option with a novel mechanism for highly active relapsing multiple sclerosis in Switzerland Approval based on extensive clinical development program capturing more than 10,000 patient years of safety data and up to 10 years of follow-up in some patients MAVENCLAD® provides the possibility of up to four years of disease control with a maximum of 20 days of oral treatment administered over two years Merck, a leading science and technology company, today announced that MAVENCLAD® (cladribine tablets) has been approved for the treatment ...

Gepostet in der Kategorie Wirtschaft (Anzahl der ansichten:) 6

Ähnlich Nachrichten